- Received November 30, -0001
- Accepted November 30, -0001
- Publication August 19, 2020
- Visibility 13 Views
- Downloads 0 Downloads
- DOI 10.18231/j.ijpo.2020.075
-
CrossMark
- Citation
Reactive thrombocytosis in malignancy- Can it be a strong predictor for IT
Introduction
Thrombocytosis refers to a platelet count above the normal value with the widespread use of electronic cell counters and the subsequent availability of a platelet count as part of a ‘routine’ blood count, thrombocytosis is more often observed as an unexpected finding. Thus, an elevated platelet count has become an important clinical problem for differential diagnosis. The association of thrombocytosis with malignancies has been known for more than 100 years.[1] Secondary thrombocytosis associated with malignancy, chronic infection, iron deficiency or chronic inflammatory diseases may persist for a longer time. Thrombocytosis was reported in patients with lung,[2] colon,[2] renal cell carcinomas,[3] cervical cancer,[4], [5] ovarian cancer[6] and vulval cancers.[7]
Materials and Methods
The study was conducted over a period of 16 months in a tertiary care hospital. A total of 500 patients who had come to OPD or admitted patients having reactive thrombocytosis were taken up for the study. All the samples which were received by the Central Diagnostic Laboratory, with requisition form for investigations from the respective OPD’s or wards and were found to have accidental thrombocytosis were taken. The cause for thrombocytosis was found to be reactive after taking the clinical details from the consulting physicians or surgeons. The information was collected and compiled in the master chart & further subjected to statistical analysis. Statistical analysis was done using the Cross tabulations for categorical data & correlation for continuous data in the SPSS ver.19 programme. Following parameter were included in my study: HISTOGRAM- The sample was run on the automated blood cell counter (Sysmex KX-21, K-1000) to know the platelet count, WBC, and MPV
Inclusion criteria
All patients who had come to the OPD and patients admitted in hospital (booked or emergency) having reactive thrombocytosis (platelet count >450,000/μl).
Exclusion criteria
Patients having platelet count more than 4.5 lakh/μl, but this was normal for their age as in paediatrics. Patient having thrombocytosis due to Myeloproliferative disorders (polycythemia vera, chronic myeloid leukaemia, chronic idiopathic myelofibrosis, essential thrombocytosis). Patient having thrombocytosis which is autonomous (primary) and not reactive (secondary).
Results
A total of 500 patients with the platelet count >450,000/ul was observed during the study period. Majority of the cases were between 38-56 years (31%) and 19-37 years (26%) ([Table 1]). Almost equal numbers of cases were studied in both the genders, males (50.8%) and females (49.2%) ([Figure 1]).
Causes of reactive thrombocytosis were as follows: infections (28.8%), tissue damage (16.4%), iron deficiency anemia (16.2%), malignancy (9.6%) and inflammation (9.4%), diabetes mellitus (6.4%), tuberculosis (6.0%), poisoning (2.0%), haemolytic anemia (1.8%), post splenectomy(1.0), hemorrhage (0.8%), myocardial infarction (0.4%), benign tumours(0.4%) low birth weight, megaloblastic anemia, CCF and drug reaction (0.2%) each respectively.
In malignancy, carcinoma oral cavity 20.8%, carcinoma breast 14.6% and carcinoma lung 14.6% were found to be more commonly associated with reactive thrombocytosis ([Table 2]). Only (4.2%) cases were studied in paediatric age group rest of the cases (95.8%) were adults ([Table 3]).
| S. No. | Age in years | No. of cases | Percentage% |
| 1. | 0 - 18 years | 105 | 21.0 |
| 2. | 19 - 37 years | 129 | 25.8 |
| 3. | 38 - 56 years | 155 | 31.0 |
| 4. | 57 - 75 years | 97 | 19.4 |
| 76 - 94 years | 14 | 2.8 | |
| Total | 500 | 100.0 |
Almost equal number of cases was studied in both the genders, males (50.8%) and females (49.2%).
| S. No. | Disease | No. of cases | Percentage% |
| 1. | Carcinoma oral cavity | 10 | 20.8 |
| 2. | Carcinoma breast | 7 | 14.6 |
| 3. | Carcinoma lung | 7 | 14.6 |
| 4. | Carcinoma cervix | 2 | 4.1 |
| 5. | Carcinoma maxilla | 2 | 4.1 |
| 6. | Carcinoma oesophagus | 2 | 4.1 |
| 7. | Carcinoma of post cricoid region | 2 | 4.1 |
| 8. | Hepatocellular carcinoma | 1 | 2.1 |
| 9. | Adenocarcinoma of ampulla of vater | 1 | 2.1 |
| 10. | Borderline metaplastic brennertumor | 1 | 2.1 |
| 11. | Carcinoma penis | 1 | 2.1 |
| 12. | Carcinoma stomach | 1 | 2.1 |
| 13. | Carcinoma testis | 1 | 2.1 |
| 14. | Extraskeletal Ewing's sarcoma of left popliteal region | 1 | 2.1 |
| 15. | Hodgkin's Lymphoma of right cervical lymph node | 1 | 2.1 |
| 16. | Leiomyosarcoma | 1 | 2.1 |
| 17. | Malignant small round cell tumor of chest wall | 1 | 2.1 |
| 18. | Metastasis carcinoma to left level IIA lymph node | 1 | 2.1 |
| 19. | Metastasis of poorly differentiated Carcinoma | 1 | 2.1 |
| 20. | Metastasis of poorly differentiated SCC, in frontal lobe | 1 | 2.1 |
| 21. | Squamous cell carcinoma of genital region | 1 | 2.1 |
| 22. | Transitional cell carcinoma of bladder | 1 | 2.1 |
| 23. | Unknown primary malignancy | 1 | 2.1 |
| Total | 48 | 100 |
| S. No | Causes | 0 -18years | >18years | Total | |||
| No. | % | No. | % | No. | % | ||
| 1. | Neoplastic a) Malignant | 2 | 4.2 | 46 | 95.8 | 48 | 100 |
| b) Benign | 2 | 100 | 0 | 0 | 2 | 100 |
Discussion
Given the importance of platelets, thrombocytosis serves as a pathological clue to diagnosis. In the present study the most common cause of reactive thrombocytosis was found to be infection 28.8% and malignancy accounted for 9.6% cases.
Among the malignant lesions, carcinoma oral cavity 20.8%, carcinoma breast 14.6% and carcinoma lung 14.6% were found to be more commonly associated with reactive thrombocytosis. This was similar to the study conducted by Levine S P et al[8] which showed that malignancy of lung and breast were more frequently associated with reactive thrombocytosis.
Our study examined the correlation between neoplasm and reactive thrombocytosis. Although there are several studies suggesting that platelets increase in various organ cancers, there were also some studies suggesting no change in platelet count in colon cancer, breast carcinoma, and gastric cancer.[9], [10], [11]
The relation between platelets and cancer progression suggests a possible role that extends beyond their hemostatic function. Platelets secrete cytokines and growth factors such as transforming growth factor-β, vascular endothelial growth factor (VEGF), matrix metalloproteinase-2, platelet factor-4, and platelet-derived growth factor which in turn induce hallmarks of cancer progression such as epithelial–mesenchymal transition, angiogenesis, cell migration, and/or proliferation and also facilitate the retention of tumor emboli in microcirculation.[12] Platelets also stimulate the release of pro-inflammatory cytokines (interleukin 1, 3, and 6) by cancer cells.[13] Thus, platelets are essential and have a multifunctional role in cancer development.
Thrombocytosis and oral cavity carcinoma
In my study carcinoma oral cavity was most commonly associated with reactive thrombocytosis, as it is the most common malignancy in India due to tobacco chewing. Association of reactive thrombocytosis with carcinoma oral cavity was also studied by Kannar V, Raja V, Suresh TN et al.[14]
Thrombocytosis and lung carcinoma
In an almost similar study done by Patel A, Abdeen Y, et al[15] the predictive role of thrombocytosis in identifying patients with advanced lung carcinoma in an urban medical center was studied.Thus concluding that accidental reactive thrombocytosis can be used as a diagnostic clue as well as predicator of malignancy.
In the present study 14.6% cases of breast malignancy having reactive thrombocytosis were found. A similar correlation between platelet count and breast neoplasms was found by Harano K, Kogawa T et al,[16] who studied platelet count as a prognostic factor in breast carcinoma.
Thus thrombocytosis appears to be a universal marker of adverse outcomes in cancer. Its association with worse oncologic outcomes has been also reported in early and advanced breast cancer,[17], [18] ovarian cancer,[19], [20] genitourinary cancers[21], [22] and several other types of cancer.[23], [24]
Conclusion
Thrombocytosis is observed in many types of malignancies and many studies have indicated that an elevated platelet count may help in giving a clue for diagnosis and prognosis of malignancy. The prevalence of thrombocytosis associated with various cancers portrays a worse survival, independent of other clinical or biochemical factors. With further studies, this single independent prognostic factor may provide a simple approach to improved risk stratification of patients in future clinical trial protocols. Utility of platelet indices in diagnosis of cancer, determination of recurrence and in follow-up treatment, needs to be evaluated by further studies conducted on a larger population.
Source of Funding
None.
Conflict of Interest
None.
References
- L Reiss. Zur Pathologischen Anatomie Des Blutes. Arch Anat Physiol Wiss Med 1872. [Google Scholar]
- Vincenzo Costantini, Leo R Zacharski, Thomas E Moritz, Richard L Edwards. The Platelet Count in Carcinoma of the Lung and Colon. Thromb Haemost 1990. [Google Scholar]
- N.P. Symbas, M.F. Townsend, R. El-Galley, T.E. Keane, S.D. Graham, J.A. Petros. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 2000. [Google Scholar]
- G C Rodriguez, D L Clarke-Pearson, J T Soper, A Berchuck, I Synan, R K Dodge. The negative prognostic implications of thrombocytosis in women with stage IB cervical cancer. Obstet Gynecol 1994. [Google Scholar]
- Enrique Hernandez, Kathleen A. Donohue, Lisa L. Anderson, Paul B. Heller, Frederick B. Stehman. The Significance of Thrombocytosis in Patients with Locally Advanced Cervical Carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol 2000. [Google Scholar]
- Alain G. Zeimet, Christian Marth, Elisabeth Müller-Holzner, Günter Daxenbichler, Otto Dapunt. Significance of thrombocytosis in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1994. [Google Scholar]
- Lukas Hefler, Klaus Mayerhofer, Ben Leibman, Andreas Obermair, Alexander Reinthaller, Christian Kainz. Tumor Anemia and Thrombocytosis in Patients with Vulvar Cancer. Tumor Biol 2000. [Google Scholar]
- S P Levine. . Thrombocytosis. Wintrobe’s Clinical Hematology A Waverly Company 1993. [Google Scholar]
- J Y Li, Y Li, Z Jiang, R T Wang, X S Wang. Elevated mean platelet volume is associated with presence of colon cancer. Asian Pac J Cancer 2014. [Google Scholar]
- Yildiz Okuturlar, Meral Gunaldi, Elif Eda Tiken, Bugra Oztosun, Yesim Ozdem Inan, Tarik Ercan. Utility of Peripheral Blood Parameters in Predicting Breast Cancer Risk. Asian Pac J Cancer Prev 2015. [Google Scholar]
- Joanna Matowicka-Karna, Zbigniew Kamocki, Beata Polińska, Joanna Osada, Halina Kemona. Platelets and Inflammatory Markers in Patients with Gastric Cancer. Clin Dev Immunol 2013. [Google Scholar] [Crossref]
- Katerina Pilatova, Kristina Greplova, Regina Demlova, Beatrix Bencsikova, Giannoula Lakka Klement, Lenka Zdrazilova-Dubska. Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology. J Hematol Oncol 2013. [Google Scholar]
- Daniel Buergy, Frederik Wenz, Christoph Groden, Marc A. Brockmann. Tumor-platelet interaction in solid tumors. Int J Cancer 2012. [Google Scholar]
- Vidyavathi Kannar, Veena Raja, TurvekereNarayanrao Suresh. Evaluation of platelet indices in oral squamous cell carcinoma. Clin Cancer Investig J 2017. [Google Scholar]
- Hamid Shaaban, Alpa Patel, Yazan Abdeen, Ram Katpally, Sugabramya Kuru, Mohammed Al Halawani. The predictive role of thrombocytosis in identifying patients with advanced lung carcinoma in an urban medical center. Clin Cancer Investig J 2016. [Google Scholar]
- Kenichi Harano, Takahiro Kogawa, Jimin Wu, Ying Yuan, Evan N. Cohen, Bora Lim. Thrombocytosis as a prognostic factor in inflammatory breast cancer. Breast Cancer Res Treat 2017. [Google Scholar]
- Athina Stravodimou, Ioannis A. Voutsadakis. Pretreatment Thrombocytosis as a Prognostic Factor in Metastatic Breast Cancer. Int J Breast Cancer 2013. [Google Scholar] [Crossref]
- Andreas Salat, Michael Gnant, Werner Kwasny, Brigitte Mlineritsch, Rainer-Christian Menzel, Marianne Schmid. Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Hemost 2003. [Google Scholar]
- R L Stone, A M Nick, I A Mcneish, F Balkwill, H D Han, J Bottsford-Miller. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012. [Google Scholar]
- A Digklia, I A Voutsadakis. Pretreatment thrombocytosis in advanced ovarian cancer. ECCO Congress. 2013. [Google Scholar]
- N.P. Symbas, M.F. Townsend, R. El-Galley, T.E. Keane, S.D. Graham, J.A. Petros. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 2000. [Google Scholar]
- Tilman Todenhöfer, Markus Renninger, Christian Schwentner, Arnulf Stenzl, Georgios Gakis. A new prognostic model for cancer-specific survival after radical cystectomy including pretreatment thrombocytosis and standard pathological risk factors. BJU Int 2012. [Google Scholar]
- Enrique Hernandez, Marc Lavine, Charles J. Dunton, Edward Gracely, Janet Parker. Poor prognosis associated with thrombocytosis in patients with cervical cancer. Cancer 1992. [Google Scholar]
- A Maráz, J Furák, Z Varga, Z Kahán, L Tiszlavicz, K Hideghéty. Thrombocytosis has a negative prognostic value in lung cancer. Anticancer Res 2013. [Google Scholar]